1615

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MARENICK, Michael et al.
Serial No.:	10/039,793
Filed:	January 8, 2002
Title:	HYDROLIZED WHOLE EGG PRODUCTS & RELATED METHODS
Art Unit:	1615 Atty Docket No.: P-0022US

CERTIFICATE OF TELEFACSIMILE & FIRST CLASS MAILING

Date of Deposit: March 1, 2002

I hereby certify that the following attached paper (s) and/or fee

(1) Request To Merge Duplicate Application;
(2) Power of Attorney; and
(3) A self-addressed stamped postcard, return which is requested to acknowledge receipt of the enclosed documents

Are being faxed to Gena Jones at (703) 872-9404 and being deposited in the United States Postal Service First Class Mail on the date indicated above and is addressed to the "Assistant Commissioner of Patents, Washington, DC 20231".

Respectfully submitted,

Dated: March 1, 2002

Dan M. de la Rosa

CORRESPONDENCE:
Dan M. de la Rosa
345 East 80th St., Suite 27H
New York, NY 10021
Phone (212) 570-6597
Fax (212) 570-9053

#2 3/19/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MARENICK, Michael et al.
Serial No.:	10/039,793
Filed:	January 8, 2002
Title:	HYDROLIZED WHOLE EGG PRODUCTS & RELATED METHODS
Art Unit:	1615

Atty Docket No.: P-0022US

REQUEST TO MERGE DUPLICATE APPLICATION

The Applicants hereby request that U.S. Patent Application Serial Number 10/052,756 with a filing date of January 23, 2002 ('756 Application) be merged with the above referenced application. The '756 Application is a duplicate copy of the above referenced application.

Respectfully submitted,

Dated: March 1, 2002

Dan M. de la Rosa
Reg. No. 38,429
345 East 80th St., Suite 27H
New York, NY 10021
Phone (212) 570-6597
Fax (212) 570-9053

L'AVENIR, LLC
1275 Bloomfield Avenue
Bldg. 9, #86
Fairfield, New Jersey 07004
Phone: (973) 227-9009
Fax: (973) 227-9077

December 21, 2001

United States Patent & Trademark Office
Assistant Commissioner of Patents
Washington, DC 20231

Re: Missing Patent Application

Dear Sir or Ma'am:

The following attached patent application entitled "Hydrolyzed Whole Egg Products & Related Methods" was mailed via First Class Mail on **October 23, 2001** (as evidenced by the attached Certificate of First Class Mailing and a Receipt from the US Postal Service of such mailing). The above application is related to Provisional Application Number 60/298,874. We did not receive the self-addressed stamped return postcard and the enclosed check for $797.00 was not cashed. This leads us to believe that the originally filed application did not reach the Patent Office. Would you kindly check into this application to see if it were formally received and mail to us the attached self-address postcard with a newly assigned Serial Application Number. I am enclosing a new check for $797 to cover the filing and assignment fees. If the originally mailed application is found, please discard the first check. If the originally mailed application is not found, we will refile original executed copies of the declarations and assignments at a later date. Thank you kindly for your assistance.

Sincerely yours,



Dan de la Rosa
L'Avenir, LLC

cc: Michael Marenick

***** WELCOME TO *****
NORTH HACKENSACK STATION
RIVER EDGE, NJ 07661-9998
10/23/01 09:23AM

Store	USPS	Trans	3
Wkstn	sys5002	Cashier	KX2P5J
Cashier's Name	RICH		
Stock Unit Id	WINRR		
PO Phone Number	201-342-0926		

		1.95
1. First Class		
Destination:	20231	
Weight:	7.10oz	
Postage Type:	PVI	
Total Cost:	1.95	
Base Rate:	1.95	
Subtotal		1.95
Total		1.95
Cash		20.00
Change Due		18.05
Cash		

Number of Items Sold: 1

Thank You
Please come again!

J1131 U.S. PTO
01/23/02

H

Utility Patent Application Transmittal

Attorney Docket No. P-0022US
First Inventor or Application Identifier
MARENICK, Michael et al.
Title HYDROLIZED WHOLE EGG PRODUCTS + RELATED METHODS
Express Mail Label No.

COPY OF PAPERS ORIGINALLY FILED

J1092 U.S. PTO
10/052756
01/23/02

APPLICATION ELEMENTS

See MPEP chapter 6000 concerning utility patent application contents.

1. [X] *Fee Transmittal Form *(e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)*
2. [X] Specification [Total pages 28] *(preferred arrangement set forth below)*
   - Descriptive title of the Invention
   - Cross References to Related Applications
   - Statement Regarding Fed sponsored R & D
   - Reference to Microfiche Appendix
   - Background of the Invention
   - Brief Summary of the Invention
   - Brief Description of the Drawings (if filed)
   - Detailed Description
   - Claim(s)
   - Abstract of the Disclosure
3. [X] Drawing(s) (35 U.S.C. 113) [Total Sheets 0]
4. Oath or Declaration
   a. [ ] Newly executed (original or copy)
   b. [ ] Copy from a prior application (37 C.F.R §1.63(d)) *(for continuation/divisional with box 16 completed)*
      i. [ ] DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R §§1.63(d)(2) and 1.33 (b).

* NOTE FOR ITEMS 1&13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. §1.28).

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

5. [ ] Microfiche Computer Program *(Appendix)*
6. Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*
   a. [ ] Computer Readable Copy
   b. [ ] Paper Copy (identical to computer copy)
   c. [ ] Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. [X] Assignment Papers (cover sheet & document(s))
8. [ ] 37.C.F.R. §3.73(b) Statement [ ] Power of Attorney *(When there is an assignee)*
9. [ ] English Translation Document *(if applicable)*
10. [ ] Information Disclosure Statement (IDS)/PTO-1449 [ ] Copies of IDS Citations
11. [ ] Preliminary Amendment
12. [X] Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
13. [X] *Small Entity Statement(s) [ ] Statement filed in prior application, Status still *(PTO/SB/09-12)* proper and desired
14. [ ] Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
15. [ ] Other:

RELATED

16. If a ~~CONTINUING~~ APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:
[ ] Continuation [ ] Divisional [ ] Continuation-in-part (CIP) of prior Provisional Application No. 60/298,814

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplies under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted fro the submitted application parts.

CORRESPONDENCE ADDRESS

FEE TRANSMITTAL
f r FY 1999

Patent fees are subject to annual revision.
Small Entity payments must be supported by a small entity statement, otherwise large entity fees must be paid. See Forms PTO/SB/09-12.

Complete if Known

Application Number To Be Assigned
Filing Date October 23, 2001
First Named Inventor MARENICK, Michael et al
Examiner Name To Be Assigned
Group / Art Unit To Be Assigned
Attorney Docket No. P-0022US

METHOD OF PAYMENT (check one)

1. [ ] The Commissioner is hereby authorized to charge indicated fees and credit any over payment to:
Deposit Account No. _____
Deposit Account Name _____

[ ] Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

2. [X] Payment Enclosed:
[X] Check [ ] Money Order [ ] Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
101	760	201	380	Utility filing fee	$ 370
106	310	206	155	Design filing fee	
107	480	207	240	Plant filing fee	
108	760	208	380	Reissue filing fee	
114	150	214	75	Provisional filing fee	
				SUBTOTAL (1)	$ 370

2. EXTRA CLAIM FEES

	Extra claims		Fee from below		Fee Paid
Total Claims	35 -20**	=	15	x 9 =	135
Independent Claims	9 -3**	=	6	x 42 =	252
Multiple Dependent				=	

**or number previously paid, if greater; For Reissues, see below

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
101	760	201	380	Utility filing fee	
106	310	206	155	Design filing fee	
107	480	207	240	Plant filing fee	
108	760	208	380	Reissue filing fee	
114	150	214	75	Provisional filing fee	
				SUBTOTAL (1)	$

FEE CALCULATION

3. ADDITIONAL FEES

Large Entity Fee Code	Large Entity Fee ($)	Small Entity Fee Code	Small Entity Fee ($)	Fee Description	Fee Paid
105	130	205	65	Surcharge-late filing fee or oath	
127	50	227	25	Surcharge-late prov provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after to Examiner action	
115	110	215	55	Extension for reply within first month	
116	380	216	190	Extension for reply within second month	
117	870	217	435	Extension for reply within third month	
118	1,360	218	680	Extension for reply within fourth month	
128	1,850	228	925	Extension for reply within fifth month	
119	300	219	150	Notice of Appeal	
120	300	220	150	Filing a brief in support of an appeal	
121	260	221	130	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceedings	
140	110	240	55	Petition to revive-unavoidable	
141	1,210	241	605	Petition to revive- unintentional	
142	1,210	242	605	Utility issue fee (or reissue)	
143	430	243	215	Design issue fee	
144	580	244	290	Plant issue fee	
122	130	122	130	Petition to the Commissioner	
123	50	123	50	Petitions related to provisional applications	
126	240	126	240	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per Property (times number of properties)	40
146	760	246	380	Filing a submission after final rejection (37 CFR 1.129(a))	
149	760	249	380	For each additional invention to be examined (37 CFR 1.129(a))	
				Other fee (specify)	
				Other fee (specify)	

* Reduced by Basic Filing Fee Paid SUBTOTAL $ 40

TOTAL AMOUNT [redacted]
$797.00

SUBMITTED BY				Complete (if applicable)	
Typed or Printed Name	Michael Marenick			Reg. Number	
Signature		Date	10/23/01	Deposit Account User ID	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MARENICK, Michael et al.
Serial No.: To Be Assigned
Filed: October 23, 2001
Title: HYDROLIZED WHOLE EGG PRODUCTS & RELATED METHODS

CERTIFICATE OF FIRST CLASS MAILING

Date of Deposit: October 23, 2001

I hereby certify that the following attached paper (s) and/or fee

(1) Utility Patent Application Transmittal;
(2) Declaration for Utility or Design Patent Application (37 CFR 1.63);
(3) Fee Transmittal;
(4) Assignment and Assignment Recordation Sheet;
(5) Patent Application (Comprising 28 pgs, 19 pgs of specifications, 8 pgs of claims, 1 abstract);
(6) A check in the amount of $797.00; and
(7) A self-addressed stamped postcard, return which is requested to acknowledge receipt of the enclosed documents

Are being deposited in the United States Postal Service First Class Mail on the date indicated above and is addressed to the "Assistant Commissioner of Patents, Washington, DC 20231".

Respectfully submitted,

Dated: October 23, 2001

Dan M. de la Rosa

CORRESPONDENCE:
Lavenir, LLC
Attn: Michael Marenick
1275 Bloomfield Avenue, Bldg. 9, # 86
Fairfield, New Jersey 07004
Telephone: (973) 227-9009
Facsimile: (973) 227-9077

HYDROLIZED WHOLE EGG PRODUCTS & RELATED METHODS

Inventors: Michael Marenick
Alyson Galderisi

Filed: October 23, 2001

Docket Number: P-0022US

HYDROLYZED WHOLE EGG PRODUCTS & RELATED METHODS

RELATED APPLICATION:

This application is related to Provisional U. S. Application Serial No. 60/298,874, entitled "A SKIN CARE PRODUCT AND A METHOD OF PRODUCING SAME" which was filed on June 18, 2001.

BACKGROUND OF THE INVENTION:

FIELD OF THE INVENTION:

This invention relates to a product containing hydrolyzed whole eggs wherein the eggs are utilized as a carrier of the active ingredients in the product and is used to achieve the desired effects of the product. More specifically, the present invention relates to a hydrolyzed whole egg product for use as a cosmetic, pharmaceutical and/or medicinal product applicable for soothing sore muscles, expediting the healing and repairing process of the skin and reducing the visual appearance of cellulite.

DESCRIPTION OF THE RELATED ART:

There are numerous cosmetic and skin care products that use components of eggs as major ingredients in their formulation. For example, some cosmetic or skin care products use egg whites in their formulation. Other cosmetic and skin care products use extracts of yokes in their formulation. The use of whole egg has never been achieved since the mixing and/or shearing process of the manufacturing of the product will cause the egg components to coagulate and form mayonnaise. There have also been problems

with incorporating the whole egg in the formations since the shearing and heating process of most processes have denatured the proteins in the eggs and have inactivated the active ingredients in the egg which provides for its excellent carrier/delivery properties. In addition, there are no cosmetic, medicinal, pharmaceutical and/or cosmopharmaceutical product that utilize whole eggs as carriers for their active ingredients.

SUMMARY OF THE INVENTION:

In one embodiment, the present invention relates to a formulation comprising at least one hydrolyzed whole egg, at least one emollient substance and at least one humectant substance. The term "hydrolyzed whole egg" is defined as a whole egg consisting of egg white and the yolk, which through a special process has had the water extracted from it. For purposes of this invention, the term "emollient substance" is defined as any natural or synthetic oil and their compound equivalents. The term "humectant substance" for the purposes of this invention is defined as glycerin and/or any other chemical of natural or synthetic origin. In another embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof. In yet another embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof. In still another embodiment, the formulation can be utilized as a cosmetic, cosmopharmaceutical and pharmaceutical formulation.

In a further embodiment, the present invention relates to a formulation comprising: hydrolyzed egg and lactoferrin and/or colostrum. In still a further embodiment, the present invention provides for a formulation comprising: hydrolyzed egg, at least one emollient substance, at least one humectant substance, and lactoferrin and/or colostrum. In still another embodiment, the colostrum is bovine colostrum.

In yet a further embodiment, the present invention relates to a formulation comprising hydrolyzed whole egg and methyl sulfonyl methane (MSM). In still yet a further embodiment, the formulation comprises hydrolyzed whole egg, at least one emollient substance, at least one humectant substance, and methyl sulfonyl methane (MSM). In a further embodiment, the present invention provides a formulation comprising hydrolyzed egg, methyl sulfonyl methane (MSM) and lactoferrin and/or colostrum. In another further embodiment, the formulation comprises: hydrolyzed whole egg, at least one emollient substance, at least one humectant substance, methyl sulfonyl methane (MSM) and lactoferrin and/or colostrum. In still another embodiment, the colostrum is bovine colostrum.

In still yet another formulation, the present invention relates to a cellulite formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one aromatherapeutical substance. In a further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof. In yet a further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca

(Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.

In still yet a further embodiment, the aromatherapeutical substance is selected from a group consisting of Lavendula Angustifolia (Lavender) oil, Geranium Maculatum Oil, Citrus Grandis (Grapefruit) oil, Juniperus Communis Oil, Pimenta Acris (Bay) Oil, Lavendula Hybrida, Geranium Robertianum, Geranium Thunbergil, Citrus Aurantium Dulsis (Orange) Oil, Citrus Nobilis (Mandarin Orange) Oil, Citrus Limonum (Lemon) Oil and extracts thereof and mixtures thereof. For purposes of this invention, the term "aromatherapeutical substance" is defined as a combination of pure essental oils with aromatic properties.

In another further embodiment, the present invention relates to skin care formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one skin nourishing/wound healing substance. In still another further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof. In yet another further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.

In still yet another further embodiment, the skin nourishing/wound healing substance is selected from a group consisting of aloe barbadensis leaf juice, white willow bark, and extracts thereof and mixtures thereof. The term "skin nourishing/wound healing

substance" is defined as any material that will assist in or promote the skin healing and/or normalizing process. In another embodiment, the skin care formulation further comprises an acne drug and the formulation functions as an acne formulation. In still another embodiment, the active drug is salicylic acid.

In a further embodiment, the present invention also relates to a muscle soothing formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and a muscle soothing substance. In still a further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof. In yet a further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.

In still yet a further embodiment, the muscle soothing substance comprises a blend of Menthol, Methyl Salicylate, Eucalyptus Globulus Oil, Camphor, and Mentha Piperita (Peppermint) Oil. For purposes of this invention, the "muscle soothing substance" is defined as any active ingredient or pure substance that can penetrate and cause sensation to the muscle tissue.

In another further embodiment, the present invention relates to a hydrolyzed whole egg formulation manufactured by a method comprising: shearing a mixture of water, triethanolamine, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, stearic acid, glyceryl stearate, and propylparaben to the mixture and shearing

and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; and upon formation of the emulsion, cooling the entire formulation.

In still another further embodiment, the method further comprising adding additional substances to said formulation during said cooling process. In yet another further embodiment, the formulation made by the above method may be utilized as a cosmetic, cosmopharmaceutical and pharmaceutical formulation depending on what additional substance(s) are added to the formulation during the cooling process.

In another embodiment, the present invention relates to a skin care formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding glycerin, salicylic acid and phenoxyethyanol and shearing the entire formulation. In still another embodiment, the formulation made by the above process may be used for acne skin care.

In yet another embodiment, the present invention further relates to a muscle soothing formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding cyclomethicone, menthol, methyl salicylate, eucalyptus globules oil, camphor, peppermint oil, pheroxyethanol and chlorophyll and shearing the entire formulation.

In a further embodiment, the present invention relates to a cellulite formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, glycerin, propylene glycol and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetyl lactate, stearic acid, paraffin, sorbitan stearate, glyceryl stearate, cyclomethicone and dimethicone copotyol, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding grapefruit oil, lavender oil, geranium maculatum oil, juniperus communis oil, cumen extract, sambucus

nigra extract, caraway extract, sage extract, parsley extract, primula veris extract and phenoxyethanol and shearing the entire formulation.

In still a further embodiment, the present invention relates to a method of manufacturing a formulation, the method comprising: shearing at least one emollient substance and at least one humectant substance; adding at least one hydrolyzed whole egg to the oil phase of the mixture and then adding the oil phase to the water phase to form an emulsion; and upon formation of the emulsion, cooling the formulation. In yet a further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof. In yet another further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof. In still yet a further embodiment, the formulation may be used as a cosmetic, cosmopharmaceutical and pharmaceutical formulation depending on what additional substance(s) are added to the formulation.

DETAILED DESCRIPTION OF THE INVENTION:

As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention that may be embodied in various forms. The figures are not necessary to scale, some features may be exaggerated to show details of particular components. Therefore, specific structural and functional details disclosed herein are not to be

interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention.

The present invention provides cosmetic, cosmopharmaceutical and pharmaceutical formulations containing hydrolyzed whole egg(s). Whole eggs are a great source of nutrients and function as carriers/deliverers of various active and inactive ingredients to the respective human/animal bodily components, organs, tissues, cells, etc. The present invention utilizes chicken eggs but can use any and all types of eggs, including but not limited to, poultry and reptile eggs.

The formulation of the present invention includes, but is not limited to, a skin care formulation, a muscle soothing formulation and a cellulite formulation. There are three unique products, discussed in detail below, that have radically different functions ranging from soothing sore muscles, to expediting the repairing process of the skin and reducing the visual appearance of cellulite. The common factor that is shared by all of these products is the use of the hydrolyzed whole egg to achieve the desired effects in each case and the unique processing method of incorporating the egg within the formulation and allowing the whole egg to act as a carrier of the active ingredients in each case.

The specific examples below will enable the present invention to be better understood. However, they are given merely by way of guidance and do not imply any limitation to this invention.

EXAMPLE 1:

HEALFAST™ Skin Care Formulation

The skin care formulation of the present invention is designed to treat eczema, psoriasis, sunburns, razor burns, blisters, acne, insect bites, burns, cuts, bruises and dry skin. The skin care formulation of the present invention, may be manufactured by the following process: shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding glycerin, salicylic acid and phenoxyethyanol and shearing the entire formulation. **Table 1** below indicates the ingredients of the skin care product of the present invention including the sequence of addition into the formulation and the %W/W of each ingredient relate to the entire formulation.

TABLE 1

Skin Care Ingredients for HEALFAST™ Formulation

SEQUENCE	TRADENAME	INCI NAME	%W/W
1	Water	Water (Aqua)	50-80
1	Triethanolamine 99%	Triethanolamine	0.05-5.00

1	Hampene Na3T	Trisodium EDTA	0.10-1.00
1	Glycerin	Glycerin	0.10-3.00
1	Methylparaben	Methylparaben	0.10-5.00
2	Lipowax D	Cetearyl Alcohol (and) Ceteareth-20	0.10-5.00
2	Sweet Almond Oil	Sweet Almond (Prunus Amygdalus Dulcis) Oil	0.10-10.00
2	Lipocol	Cetyl Alcohol	0.10-5.00
2	Stearic Acid XXX	Stearic Acid	0.10-5.00
2	Lipomulse 165	Glyceryl Stearate (and) PEG-100 Stearate	0.10-5.00
2	Sorbitan Stearate	Sorbitan Stearate	0.10-5.00
2	Covi-ax T-50	Tocopherol	0.01-1.00
2	Vitamin A Palmitate	Retinyl Palmitate	0.10-3.00
2	BVOSC (Barnet)	Tetrahexyldecyl Ascorbate	0.10-3.00
2	Propylparaben	Propylparaben	0.10-3.00
2	Hydrolyzed Whole Egg	Hydrolyzed Whole Egg	0.10-10.00
3	Glycerin	Glycerin	0.10-5.00
3	Salicylic Acid	Salicylic Acid	0.01-0.49
4	Emmeressence 1160 Rose	Phenoxyethyanol	0.10-3.00

In another embodiment of the present invention, the above skin care formulation (HEALFAST™) may be embedded or incorporated onto a patch or bandage, which can be adhered onto the target area of the human body (for example, a cut or laceration on the forearm). The patch or bandage may be of any shape or size and it comprises an adhesive strip for attaching the pad or bandage onto the human user and a pad containing the skin care formulation, which is placed directly upon the target area. The patch or bandage may

further comprise removable tabs (which are removed at the moment of use) and a sterile wrapper or packaging.

The skin care formulation may be embedded or incorporated onto or into the pad through any and all techniques utilized in embedding medicament, ointment or other substances. The pad and adhesive strip may be constructed of any stretchable, bendable or breathable material, including various fabrics. The pad and adhesive strip may also be constructed of water resistant materials. The pad may be an absorbent cushion pad that has excellent drainage properties. The patch or bandage may be dermatologically tested and hypoallergenic.

In still another embodiment, the muscle soothing formulation and cellulite formulation discussed below may also be embedded or incorporated onto patches or bandages. Like the HEALFAST™ patches or bandages, the muscle soothing and cellulite patches or bandages may also be attached onto the target area of the human anatomy (for example, the cellulite patch may be placed upon the woman's thighs or the muscle soothing patch may be adhered to an aching back or foot). The patches may also contain concentrated amount of the formulation and based upon the formulation, the patch or bandage may be designed to be used for hours or for days and even, for weeks. The patches or bandages are utilized to apply the formulation directly onto target areas and may provide a less messy alternative to direct application of the formulation onto the user's body. The patches will also prevent contact of the formulation with the user's clothing.

EXAMPLE 2:

ULTRA SOOTHE™ Muscle Soothing Formulation

The muscle soothing formulation of the present invention is designed to treat muscle aches and pains, and is applicable for all muscle parts and joints. The muscle soothing formulation of the present invention may be manufactured by the following method: shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding cyclomethicone, menthol, methyl salicylate, eucalyptus globules oil, camphor, peppermint oil, pheroxyethanol and chlorophyll and shearing the entire formulation. **Table 2** below indicates the ingredients of the muscle soothing product of the present invention including the sequence of addition into the formulation and the %W/W of each ingredient relate to the entire formulation.

TABLE 2

Muscle Soothing Ingredients for ULTRA SOOTHE™ Formulation

SEQUENCE	TRADENAME	INCI NAME	%W/W
1	Water	Water (Aqua)	20-60
1	Glycerin	Glycerin	0.10-10.00

1	Methylparaben	Methylparaben	0.10-0.30
1	Hampene Na3T	Trisodium EDTA	0.10-0.30
1	Triethanolamine	Triethanolamine	0.01-3.00
2	Stearic Acid	Stearic Acid	0.50-5.00
2	Lipowax D	Cetearyl Alcohol (and) Ceteareth-20	2.50-7.50
2	Almond Oil	Sweet Almond (Prunus Amygdalus Dulcis) Oil	5.0-15.00
2	Lipomulse 165	Glyceryl Stearate (and) PEG-100 Stearate	3.50
2	Ceraphyl 28	Cetyl Lactate	0.30-4.00
2	Hydrolyzed Whole Egg	Hydrolyzed Whole Egg	0.10-10.00
2	Covi-ax T-50	Tocopherol	0.10-0.50
2	Vitamin A Palmitate	Retinyl Palmitate	0.10-0.50
2	BVOSC (Barnet)	Tetrahexyldecyl Ascorbate	0.10-1.00
2	Propylparaben	Propylparaben	0.10-0.30
3	Sepigel 305	Polyacrylamide (and) C13-14 Isoparaffin (and) Laureth-7	2-5
4	Dow Corning 345 Fluid	Cyclomethicone	1.00-5.00
5	Menthol	Menthol	2-10
5	Methyl Salicylate	Methyl Salcylate	2-10
5	Eucalyptus Oil	Eucalyptus Globulus Oil	0.10-5.00
5	Camphor	Camphor	2-10
5	Peppermint Oil	Peppermint (Mentha Piperita) Oil	0.10-5.00
6	Emmeressence 1160 Rose	Phenoxyethyanol	0.10-3.00
7	Chlorophyllin Coper Complex	Chlorophyll	q.s.

EXAMPLE 3:

CELLUTONE™ Cellulite Formulation

The cellulite formulation of the present invention is designed to reduce the visual appearance of cellulite. The cellulite formulation of the present invention may be manufactured by the following method: shearing a mixture of water, triethanolamine, glycerin, propylene glycol and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetyl lactate, stearic acid, paraffin, sorbitan stearate, glyceryl stearate, cyclomethicone and dimethicone copotyol, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding grapefruit oil, lavender oil, geranium maculatum oil, juniperus communis oil, cumen extract, sambucus nigra extract, caraway extract, sage extract, parsley extract, primula veris extract and phenoxyethanol and shearing the entire formulation. **Table 3** below indicates the ingredients of the cellulite product of the present invention including the sequence of addition into the formulation and the %W/W of each ingredient relate to the entire formulation.

TABLE 3

Cellulite Ingredients for CELLUTONE™ Formulation

SEQUENCE	TRADENAME	INCI NAME	%W/W
1	Water	Water (Aqua)	40-60
1	Triethanolamine 99%	Triethanolamine	0.30-3.00

1	Carbowax 400	PEG-8	0.10-10.00
1	Glycerin	Glycerin	0.50-5.00
1	Propylene Glycol	Propylene Glycol	1.00-4.00
1	Methylparaben	Methylparaben	0.10-1.00
2	Lipo GMS 450	Glyceryl Stearate	0.25-5.00
2	Sweet Almond Oil	Sweet Almond (Prunus Amygdalus Dulcis) Oil	0.60-6.00
2	Ceraphyl 28	Cetyl Lactate	0.50-5.00
2	Stearic Acid XXX	Stearic Acid	0.50-5.00
2	Paraffin	Paraffin	0.50-5.00
2	Sorbitan Stearate	Sorbitan Stearate	0.50-5.00
2	Propylparaben	Propylparaben	0.10-5.00
2	Dow Corning 3225C	Cyclomethicone (and) Dimethicone Copotyol	0.10-10.00
2	Hydrolyzed Whole Egg	Hydrolyzed Whole Egg	0.10-10.00
3	Grapefruit Oil	Grapefruit (Citrus) Gandis) Oil	0.10-2.00
3	Lavender Oil	Lavender (Lavendula Angustifoli) Oil	0.50-5.00
3	Geranium Oil	Geranium Maculatum Oil	0.50-5.00
3	Juniperberry Oil	Juniperus Communis Oil	0.50-5.00
4	Cumin Extract	Cumin (Cuminum Cyminum) Extract	0.50-5.00
4	Elderflower Extract	Sambucus Nigra Extract	0.50-5.00
4	Caraway Extract	Caraway (Carum Carvi) Extract	0.50-5.00

4	Sage Extract	Sage (Salvia Officinalis) Extract	0.50-5.00
4	Parsley Extract	Parsley (Carum Petroselinum) Extract	0.50-5.00
4	Cowslip Extract	Primula Veris Extract	0.50-5.00
5	Emmeressence 1160 Rose	Phenoxyethyanol	0.10-3.00

Below is a manufacturing process that is suitable for all three products which depicts a unique method of the addition of the water-soluble egg into the oil phase of the formulation at relatively high temperatures. The process allows the egg to encapsulate the oils and permits the formulation containing the encapsulated egg to penetrate into the skin and deliver the active ingredients. The egg with the encapsulated oils is termed "Eggosomes" and is formed prior to the emulsification process.

The manufacturing process of the present invention is applicable to Examples 1-3 of the present invention and relates to the ingredients and sequence of additions illustrated in Tables 1-3. The manufacturing procedure is as follows:

Into a stainless steel, jacketed kettle equipped with at least one high shear mixer and at least one planetary mixer, Sequence #1 is loaded under adequate shear and heated from about 76 degrees Celsius to about 78 degrees Celsius. (For purposes of this invention, adequate shear is defined as from about 800 to about 2000 RPMs).

After adequate shearing and heating of Sequence #1, Sequence #2 is then loaded into the kettle and is further heated from about 82 degrees Celsius to about 86 degrees

Celsius, with adequate shear. (For purposes of this invention, adequate shear is defined as from about 800 to about 2000 RPMs).

When the kettle reaches its optimum temperatures, the hydrolyzed whole egg is added to the oil phase kettle and the heating is stopped. The hydrolyzed egg is gently stirred into the oil, and is evenly coated with the oil, but not burned (this is known as the formation of the "Eggosome"). Within seconds, the oil phase is added to the water phase, thus completing the "Eggosome" or carrier vehicle. The emulsion is formed. The temperature and energy are carefully monitored to ensure that a small particle is formed (this can be confirmed under the microscope).

Once the emulsion is formed, the cooling process begins and the process may then be continued until the phases of the formula are further added.

The "Eggosome" or "Ovasome" of the present invention is capable of carrying and delivering any and all types of ingredients, active and inactive, natural and synthetic, drugs, nutrients, or bioactives. The formulation of the present invention can also be modified to function as a cosmetic and/or pharmaceutical formulation depending on the additional ingredients added to this unique manufacturing process and depending on what ingredients may be desired to be delivered to a human or animal target. In one embodiment, the formulation of the present invention may be simply applied to the skin and the semi-permeable nature of the skin will allow entrance of the formulation and the "Eggosome" or "Ovasome" will then be able to deliver the desired material to the desired target. Since the "Eggosome" or "Ovasome" is capable of carrying various ingredients including active drugs, the formulation of the present invention may also have medicinal

applications. The present invention may also include accelerated healing ingredients that may be applied to adhesive patches and bandages for commercial and hospital use.

Numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the attendant claims attached hereto, this invention may be practiced otherwise than as specifically disclosed herein.

CLAIMS:

What Is Claimed Is:

1. A formulation comprising at least one hydrolyzed whole egg, at least one emollient substance and at least one humectant substance.

2. The formulation of Claim 1 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.

3. The formulation of Claim 1 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil, synthetic oils and extracts thereof and mixtures thereof.

4. The formulation of Claim 1 wherein said formulation is a cosmetic formulation.

5. The formulation of Claim 1 wherein said formulation is a cosmopharmaceutical formulation.

6. The formulation of Claim 1 wherein said formulation is a pharmaceutical formulation.

7. A cellulite formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one aromatherapeutical substance.

8. The formulation of Claim 7 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.

9. The formulation of Claim 7 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.

10. The formulation of Claim 7 wherein said aromatherapeutical substance is selected from a group consisting of Lavendula Angustifolia (Lavender) oil, Geranium Maculatum Oil, Citrus Grandis (Grapefruit) oil, Juniperus Communis Oil, Pimenta Acris (Bay) Oil, Lavendula Hybrida, Geranium Robertianum, Geranium Thunbergil, Citrus Aurantium Dulsis (Orange) Oil, Citrus Nobilis (Mandarin Orange) Oil, Citrus Limonum (Lemon) Oil and extracts thereof and mixtures thereof.

11. A skin care formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one skin nourishing/wound healing substance.

12. The formulation of Claim 11 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.

13. The formulation of Claim 11 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.

14. The formulation of Claim 11 wherein said skin nourishing/wound healing substance is selected from a group consisting of aloe barbadensis leaf juice, white willow bark, and extracts thereof and mixtures thereof.

15. The formulation of Claim 11 further comprising an acne drug and said formulation functions as an acne formulation.

16. The formulation of Claim 15 wherein said active drug is salicylic acid.

17. A muscle soothing formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and a muscle soothing substance.

18. The formulation of Claim 17 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.

19. The formulation of Claim 17 said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.

20. The formulation of Claim 17 wherein said muscle soothing substance comprises a blend of Menthol, Methyl Salicylate, Eucalyptus Globulus Oil, Camphor, and Mentha Piperita (Peppermint) Oil.

21. A hydrolyzed whole egg formulation manufactured by a method comprising:

shearing a mixture of water, triethanolamine, glycerin and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;

adding sweet almond oil, stearic acid, glyceryl stearate, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;

adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; and

upon formation of the emulsion, cooling the entire formulation.

22. The formulation of Claim 21 further comprising adding additional substances to said formulation during said cooling process.

23. The formulation of Claim 21 wherein said formulation is a cosmetic formulation.

24. The formulation of Claim 21 wherein said formulation is a cosmopharmaceutical formulation.

25. The formulation of Claim 21 wherein said formulation is a pharmaceutical formulation.

26. A skin care formulation manufactured by a process comprising:

shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;

adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;

adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion;

upon formation of the emulsion, cooling the entire formulation; and

adding glycerin, salicylic acid and phenoxyethyanol and shearing the entire formulation.

27. The formulation of Claim 26 wherein said formulation is used for acne skin care.

28. A muscle soothing formulation manufactured by a process comprising:

shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;

adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;

adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion;

upon formation of the emulsion, cooling the entire formulation; and

adding cyclomethicone, menthol, methyl salicylate, eucalyptus globules oil, camphor, peppermint oil, pheroxyethanol and chlorophyll and shearing the entire formulation.

29. A cellulite formulation manufactured by a process comprising:

shearing a mixture of water, triethanolamine, glycerin, propylene glycol and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;

adding sweet almond oil, cetyl lactate, stearic acid, paraffin, sorbitan stearate, glyceryl stearate, cyclomethicone and dimethicone copotyol, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;

adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion;

upon formation of the emulsion, cooling the entire formulation; and

adding grapefruit oil, lavender oil, geranium maculatum oil, juniperus communis oil, cumen extract, sambucus nigra extract, caraway extract, sage extract, parsley extract, primula veris extract and phenoxyethanol and shearing the entire formulation.

30. A method of manufacturing a formulation, said method comprising:

shearing at least one emollient substance and at least one humectant substance;

adding at least one hydrolyzed whole egg to the oil phase of the mixture and then adding the oil phase to the water phase to form an emulsion; and

upon formation of the emulsion, cooling said formulation.

31. The method of Claim 30 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.

32. The method of Claim 30 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.

33. The method of Claim 30 wherein said formulation is a cosmetic formulation.

34. The method of Claim 30 wherein said formulation is a cosmopharmaceutical formulation.

35. The method of Claim 30 wherein said formulation is a pharmaceutical formulation.

ABSTRACT OF THE INVENTION:

The present invention provides a formulation comprising hydrolyzed whole egg, an emollient substance and a humectant substance; and provides a method of incorporating a hydrolyzed whole egg into a cosmetic, pharmaceutical and medicinal formulation wherein the hydrolyzed whole egg acts as a nutrient source and as a carrier of the active ingredients in the formulation to desired bodily targets.

DECLARATION [redacted] UTILITY OR DESIGN PAT[redacted] APPLICATION
(37 CFR 1.63)

Attorney Docket No.: P-0022-US

First Named Inventor: MARENICK, Michael, et al.

Application No.: To Be Assigned

Filling Date: October 23, 2001

Group Art Unit: To Be Assigned

Examiner Name: To Be Assigned

As inventor(s) named below, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HYDROLIZED WHOLE EGG PRODUCTS & RELATED METHODS

The specification of which;

a. [x] is attached hereto.

b. [ ] was filed on

PCT FILED APPLICATION ENTERING NATIONAL STAGE

c. [ ] was described and claimed in International Application No. _____ filed on _____ as amended on _____ (if any)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that those statements were made with the knowledge that willful false statements and the like, so make are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby specify the following as the correspondence address to which all communications about this application are to be directed:

Lavenir, LLC
Attn: Michael Marenick
1275 Bloomfield Avenue, Bldg. 9, # 86
Fairfield, New Jersey 07004
Telephone: (973) 227-9009
Facsimile: (973) 227-9077

Full name of sole or first inventor: Michael Marenick

Inventor's Signature: _____ Date: 10/19/01

Residence: 1275 Bloomfield Avenue, Fairfield, New Jersey 07004

Citizenship: U.S.A Country: U.S.A

Post Office Address:

Second inventor: Alys[redacted]lderisi

Inventor's Signature: Alyssa Galderisi Date: 10/19/01

Residence: 24 Packanack Lake Road, Wayne, New Jersey 07470

Citizenship: U.S.A Country: U.S.A

Post Office Address_____